CPT1A

Across TCGA pan-cancer cohorts, CPT1A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPT1A data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CPT1A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPT1A expression acts as an unfavorable survival marker, although some lineages such as OV and HNSC show a favorable association.

LUAD, OV, and COAD are the cancer types where CPT1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.540	0.731	.017	18	view →
OV	DFS	Tertile	All	0.884	0.456	.014	8	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	2	view →
CCRCC	OS	Quartile	II,III,IV	0.746	1.000	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPT1A–LUAD (DFS)

Open the LUAD breakdown →